The observed increased risk of acute kidney injury with the GnRH antagonist degarelix is difficult to interpret as it was one of a number of analyses, based upon relatively few acute kidney injury events and because degarelix users are likely to have more advanced prostate cancer. This evidence concerns the gene GNRH1 and Familial prostate cancer.